Abstract |
Dopamine deficiency, caused by the degeneration of nigrostriatal dopaminergic neurons, is the cause of the major clinical motor symptoms of Parkinson's disease. These symptoms can be treated successfully with a range of drugs that include levodopa, inhibitors of the enzymatic breakdown of levodopa and dopamine agonists delivered by oral, subcutaneous, transcutaneous, intravenous or intra-duodenal routes. However, Parkinson's disease involves degeneration of non-dopaminergic neurons and the treatment of the resulting predominantly non-motor features remains a challenge. This review describes the important recent advances that underlie the development of novel dopaminergic and non- dopaminergic drugs for Parkinson's disease, and also for the motor complications that arise from the use of existing therapies.
|
Authors | Anthony H V Schapira, Erwan Bezard, Jonathan Brotchie, Frédéric Calon, Graham L Collingridge, Borris Ferger, Bastian Hengerer, Etienne Hirsch, Peter Jenner, Nicolas Le Novère, José A Obeso, Michael A Schwarzschild, Umberto Spampinato, Giora Davidai |
Journal | Nature reviews. Drug discovery
(Nat Rev Drug Discov)
Vol. 5
Issue 10
Pg. 845-54
(Oct 2006)
ISSN: 1474-1776 [Print] England |
PMID | 17016425
(Publication Type: Journal Article, Review)
|
Chemical References |
- Adenosine A2 Receptor Antagonists
- Antiparkinson Agents
- Cholinergic Agents
- Dopamine Agonists
- Excitatory Amino Acid Antagonists
- Monoamine Oxidase Inhibitors
- Narcotic Antagonists
- Serotonin Antagonists
- Serotonin Receptor Agonists
|
Topics |
- Adenosine A2 Receptor Antagonists
- Antiparkinson Agents
(pharmacology, therapeutic use)
- Cholinergic Agents
(therapeutic use)
- Clinical Trials as Topic
- Dopamine Agonists
(therapeutic use)
- Excitatory Amino Acid Antagonists
(therapeutic use)
- Humans
- Monoamine Oxidase Inhibitors
(therapeutic use)
- Narcotic Antagonists
(therapeutic use)
- Parkinson Disease
(drug therapy)
- Serotonin Antagonists
(therapeutic use)
- Serotonin Receptor Agonists
(therapeutic use)
|